LU92782I2 - Safinamide à utiliser en combinaison avec levodopa/PDI, et éventuellement avec d'autres médicaments PD, pour le traitement de la maladie de Parkinson - Google Patents

Safinamide à utiliser en combinaison avec levodopa/PDI, et éventuellement avec d'autres médicaments PD, pour le traitement de la maladie de Parkinson Download PDF

Info

Publication number: LU92782I2
Authority: LU; Luxembourg
Prior art keywords: safinamide; levodopa; pdi; parkinson; drugs
Prior art date: 2003-04-11

Application number

LU92782C

Other languages

English (en)

French (fr)

Original Assignee

Newron Pharm Spa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-04-11

Filing date

2015-07-22

Publication date

2015-09-22

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33159845&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU92782(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2015-07-22 Application filed by Newron Pharm Spa filed Critical Newron Pharm Spa

2015-09-22 Publication of LU92782I2 publication Critical patent/LU92782I2/xx

Links

WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 title 1
WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 title 1
208000018737 Parkinson disease Diseases 0.000 title 1
229940079593 drug Drugs 0.000 title 1
239000003814 drug Substances 0.000 title 1
229960004502 levodopa Drugs 0.000 title 1
NEMGRZFTLSKBAP-LBPRGKRZSA-N safinamide Chemical compound C1=CC(CN[C@@H](C)C(N)=O)=CC=C1OCC1=CC=CC(F)=C1 NEMGRZFTLSKBAP-LBPRGKRZSA-N 0.000 title 1
229950002652 safinamide Drugs 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs

Landscapes

Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Epidemiology (AREA)
Emergency Medicine (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Psychology (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

LU92782C 2003-04-11 2015-07-22 Safinamide à utiliser en combinaison avec levodopa/PDI, et éventuellement avec d'autres médicaments PD, pour le traitement de la maladie de Parkinson LU92782I2 (fr)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US46220503P	2003-04-11	2003-04-11

Publications (1)

Publication Number	Publication Date
LU92782I2 true LU92782I2 (fr)	2015-09-22

Family

ID=33159845

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
LU92782C LU92782I2 (fr)	2003-04-11	2015-07-22	Safinamide à utiliser en combinaison avec levodopa/PDI, et éventuellement avec d'autres médicaments PD, pour le traitement de la maladie de Parkinson

Country Status (28)

Country	Link
US (3)	US8283380B2 (de)
EP (2)	EP2070526B1 (de)
JP (2)	JP2006522800A (de)
KR (2)	KR20110070929A (de)
CN (2)	CN102274517B (de)
AR (1)	AR044007A1 (de)
AT (1)	ATE435012T1 (de)
AU (1)	AU2004228782B2 (de)
BR (1)	BRPI0409364A (de)
CA (1)	CA2523188C (de)
CY (3)	CY1109295T1 (de)
DE (1)	DE602004021790D1 (de)
DK (2)	DK1613296T3 (de)
ES (2)	ES2454272T3 (de)
FR (1)	FR15C0054I2 (de)
HU (1)	HUS1500043I1 (de)
IL (2)	IL171331A (de)
LU (1)	LU92782I2 (de)
MX (1)	MXPA05010873A (de)
NL (1)	NL300752I2 (de)
NO (3)	NO334316B1 (de)
NZ (1)	NZ542910A (de)
PL (2)	PL1613296T3 (de)
PT (2)	PT1613296E (de)
RU (1)	RU2342929C2 (de)
SI (2)	SI1613296T1 (de)
TW (1)	TWI340640B (de)
WO (1)	WO2004089353A2 (de)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9727523D0 (en)	1997-12-31	1998-02-25	Pharmacia & Upjohn Spa	Alpha-aminoamide derivatives useful as analgesic agents
DK1423168T3 (da) *	2001-09-03	2006-05-15	Newron Pharm Spa	Farmaceutisk præparat omfattende gabapentin eller en analog deraf og et alfa-aminoamid og dets analgetiske anvendelse
EP1438956A1 (de) *	2003-01-16	2004-07-21	Newron Pharmaceuticals S.p.A.	Alpha-Aminoamidderivate die als Antimigränemittel nützlich sind
DK1658062T3 (da) *	2003-08-25	2010-05-31	Newron Pharm Spa	Alfa-aminoamid-derivater anvendelige som anti-inflammatoriske midler
EP1588704A1 (de)	2004-04-22	2005-10-26	Newron Pharmaceuticals S.p.A.	Alpha-aminoamidderivate zur Behandlung des Restless-Leg-Syndroms und der Suchterkrankungen
DK1809271T5 (da) *	2004-09-10	2010-12-06	Newron Pharm Spa	Anvendelse af (R)-(halogenbenzyloxy)benzylaminopropanamider som natrium- og/eller calciumkanalselektive modulatorer
US20070004639A1 (en) *	2005-07-01	2007-01-04	Bodybio, Inc.	Methods and compositions for treating Parkinson's disease
WO2007069274A2 (en) *	2005-11-09	2007-06-21	Torrent Pharmaceuticals Limited	Pharmaceutical composition comprising a compound having a catechol moiety and an alkalising agent
EP1963280B1 (de) *	2005-12-22	2015-10-28	Newron Pharmaceuticals S.p.A.	2-phenylethylaminoderivate als calcium- und/oder natrium-kanalmodulatoren
CN101032474B (zh) *	2006-03-06	2011-02-16	重庆医药工业研究院有限责任公司	一种治疗或预防神经系统疾病的雷沙吉兰透皮贴片及其制备方法
EP1870097A1 (de) *	2006-06-15	2007-12-26	Newron Pharmaceuticals S.p.A.	Alpha-aminoamidederivate zur Behandlung von kognitiven Störungen
US8106056B2 (en) *	2006-06-16	2012-01-31	Solvay Pharmaceuticals B.V.	Combination preparations comprising bifeprunox and a dopamine agonist
HUE030233T2 (en) *	2006-06-19	2017-04-28	Newron Pharm Spa	High purity 2- [4- (3- and 2-fluorobenzyloxy) benzylamino] propanamides for use as medicaments and pharmaceutical compositions containing them
DE102007014947B4 (de) *	2007-03-23	2010-05-27	Axxonis Pharma Ag	Stabilisierte wässrige Lösungen von Ergolinverbindungen
US20100092554A1 (en) *	2007-04-24	2010-04-15	Boehringer Ingelheim International Gmbh	Combination with an extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof
CA2689561C (en)	2007-06-15	2015-11-17	Newron Pharmaceuticals S.P.A.	Substituted 2- [2- (phenyl) ethylamino] alkaneamide derivatives and their use as sodium and/or calcium channel modulators
GB2453770A (en) *	2007-10-19	2009-04-22	Reckitt Benckiser Healthcare	Oral composition comprising a cooling agent
US20090149544A1 (en) *	2007-10-22	2009-06-11	Concert Pharmaceuticals, Inc.	Alpha-aminoamide derivatives
US8530701B2 (en)	2007-12-11	2013-09-10	Newron Pharmaceuticals, S.P.A.	High purity 2-[4-(3- OR 2-fluorobenzyloxy)benzylamino]propanamides and methods of use thereof
NZ586182A (en) *	2007-12-19	2012-02-24	Newron Pharm Spa	Alpha-aminoamide derivatives useful in the treatment of psychiatric disorders
WO2009122351A2 (en) *	2008-04-01	2009-10-08	Kangwon National University	Anti-parkinsonian compounds mppe
WO2009147432A1 (en) *	2008-06-02	2009-12-10	Generics [Uk] Limited	An improved process for the preparation of amines
CN103896779B (zh) *	2008-06-02	2015-12-30	基因里克斯(英国)有限公司	用于制备对映异构纯胺的方法
US8969417B2 (en) *	2008-06-06	2015-03-03	Pharmatwob Ltd.	Pharmaceutical compositions for treatment of Parkinsons disease
JP2011522892A (ja) *	2008-06-13	2011-08-04	テバファーマシューティカルインダストリーズリミティド	パーキンソン病緩和のためのラサギリン
WO2010010138A1 (en) *	2008-07-24	2010-01-28	Boehringer Ingelheim International Gmbh	Pharmaceutical composition comprising pramipexole and a calcium channel blocker for the treatment of parkinson's disease
US20100189790A1 (en)	2009-01-23	2010-07-29	Teva Pharmaceutical Industries, Ltd.	Delayed release rasagiline formulation
EP2218444A3 (de) *	2009-01-23	2010-08-25	Teva Pharmaceutical Industries, Ltd.	Rasagilinformulierung mit verzögerter Freisetzung
EP2314569A1 (de)	2009-10-22	2011-04-27	Merck Patent GmbH	Neuartige polymorphe Formen von (S)-2-[4-(3-Fluor-benzyloxy)-benzylamino]-Propionamidmesylatsalz und Herstellungsverfahren dafür
CN102048717B (zh)	2009-10-29	2014-02-19	重庆医药工业研究院有限责任公司	一种稳定的雷沙吉兰组合物
WO2011098456A1 (en) *	2010-02-09	2011-08-18	Merck Serono S.A.	Safinamide in the treatment of dyskinesia
SI2563355T1 (sl)	2010-04-27	2016-10-28	Newron Pharmaceuticals S.P.A.	Postopek za izdelavo metansulfonatnih soli ralfinamida ali njihovih R-enantiomerov
ES2608782T3 (es)	2010-04-30	2017-04-17	Teikoku Pharma Usa, Inc.	Composiciones transdérmicas de propinilaminoindano
EP2688561B1 (de)	2011-03-24	2018-08-22	Teikoku Pharma USA, Inc.	Transdermale zusammensetzungen mit einer wirkstoffschicht und einer wirkstoffumwandlungsschicht
US20150031768A1 (en) *	2011-08-19	2015-01-29	The Trustees Of Princeton University	C-halogen bond formation
US10196341B2 (en)	2011-08-19	2019-02-05	The Trustees Of Princeton University	C-halogen bond formation
JP5913614B2 (ja)	2011-11-09	2016-04-27	テイコクファーマユーエスエーインコーポレーテッド	皮膚新生物の処置方法
KR20210075224A (ko)	2012-10-22	2021-06-22	키비타스 테라퓨틱스, 인코포레이티드.	파킨슨병의 빠른 경감을 위한 레보도파 제형
AU2013338243B2 (en)	2012-11-02	2016-09-29	Teikoku Seiyaku Co., Ltd.	Propynylaminoindan transdermal compositions
US9155695B2 (en)	2013-03-14	2015-10-13	Medtronic, Inc.	Injectable ropinirole compositions and methods for making and using same
WO2014210544A2 (en) *	2013-06-27	2014-12-31	Cedars-Sinai Medical Center	Adrenoceptors antagonists for the prevention and treatment of neurodegenerative conditions
EP3134077A4 (de) *	2014-04-21	2017-12-20	Civitas Therapeutics, Inc.	Schnelle linderung von motorischen fluktuationen bei morbus parkinson
CN106795098B (zh) *	2014-10-02	2020-07-14	默加拜奥伍德有限公司	α-氨基酰胺衍生化合物及包含其的药物组合物
PT3341380T (pt) *	2015-08-27	2019-12-19	Prexton Therapeutics Sa	Derivado de oxima de cromona penetrante no cérebro para a terapêutica da discinesia induzida por levodopa
WO2017161155A1 (en) *	2016-03-17	2017-09-21	The Johns Hopkins University	Methods for preventing or treating parkinson's disease by the farnesylation of paris
ITUA20163981A1 (it)	2016-05-31	2017-12-01	Zambon Spa	Composizioni farmaceutiche comprendenti safinamide
WO2018132746A1 (en) *	2017-01-14	2018-07-19	Mischley Laurie Kathern	Method of using human excrement and secretions for early detection of parkinson's disease
CN109251155A (zh) *	2017-07-14	2019-01-22	广东东阳光药业有限公司	α-氨基酰胺衍生物及其用途
US11234961B2 (en) *	2017-08-17	2022-02-01	Zi-Qiang Gu	Pamoate salt of monoamine anti-Parkinson's agents, method of preparation and use thereof
WO2019086408A1 (en)	2017-11-02	2019-05-09	Zambon S.P.A.	Pharmaceutical compositions comprising safinamide
KR102005019B1 (ko) *	2018-04-04	2019-07-31	한국과학기술연구원	뇌졸중의 예방 및 치료용 조성물
CN119564619A (zh) *	2019-09-12	2025-03-07	阿奇维生命科学公司	治疗和/或预防有需要的受试者的成瘾的包括野靛碱的组合物
LU101477B1 (en) *	2019-11-12	2021-05-14	Univ Luxembourg	An inhibitor of an iron-containing hydrogenase of a methanogenic archaeon for use in the treatment or prevention of a parkinsonian condition
CN110938014A (zh) *	2019-11-28	2020-03-31	岳千奥	取代苯氧酰胺衍生物、应用及用于治疗帕金森病的药物
JP2023504876A (ja) *	2019-12-06	2023-02-07	シャンハイファーマシューティカルズホールディングカンパニー，リミティド	薬物組成物、キット及びその応用
CN110999980A (zh) *	2019-12-19	2020-04-14	新疆石河子职业技术学院（石河子市技工学校）	一种葡萄酒洗浸奶酪加工方法
WO2022047298A1 (en) *	2020-08-31	2022-03-03	Purdue Pharma L.P.	Compositions and methods for levodopa delivery
KR20230154249A (ko) *	2021-03-08	2023-11-07	프로테나 바이오사이언시즈 리미티드	파킨슨 질환의 치료
KR102790040B1 (ko) *	2021-06-24	2025-04-01	연세대학교 산학협력단	도파민 미모톱 기능 합성 펩티드 및 이를 포함하는 mao-b 억제제

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB1140748A (en)	1966-06-23	1969-01-22	Ici Ltd	New carboxylic acid derivatives
US3795739A (en) *	1972-02-14	1974-03-05	Hoffmann La Roche	Treatment of parkinson disease
US4049663A (en)	1972-06-06	1977-09-20	Allen & Hanburys Limited	Ethylene diamine derivatives
FR2480747A1 (fr)	1980-04-17	1981-10-23	Roques Bernard	Derives d'acides amines et leur application therapeutique
US4935429A (en)	1985-10-25	1990-06-19	Dackis Charles A	Method of treating psychostimulant addiction
DE252290T1 (de) *	1986-06-10	1988-06-09	Chiesi Farmaceutici S.P.A., Parma	Levodopa-methyl-ester enthaltende pharmazeutische zusammensetzungen, ihre herstellung und therapeutische verwendungen.
EP0331620B1 (de)	1988-03-01	1993-08-11	Birkmayer, Walther, Prof. Dr.	Mittel zur Behandlung des Parkinson-Syndroms
IL94466A (en) *	1989-05-25	1995-01-24	Erba Carlo Spa	Pharmaceutical preparations containing the history of A-amino carboxamide N-phenylalkyl are converted into such new compounds and their preparation
US5221536A (en) *	1990-05-07	1993-06-22	Alza Corporation	Dosage form indicated for the management of abnormal posture, tremor and involuntary movement
US5502658A (en)	1990-12-27	1996-03-26	Relin; Arkadi	Sampled-continuous probability method of velocity measurement of the object having informatively-structural inhomogeneity
GB9306886D0 (en)	1993-04-01	1993-05-26	Erba Carlo Spa	Substituted (arylakoxybenzyl) aminopropanamide derivatives and process for their preparation
IL111240A (en) *	1993-10-18	2001-10-31	Teva Pharma	Salts of r(+) - enantiomers of n- propargyl-1-aminoindan and pharmaceutical compositions comprising them
ATE258067T1 (de) *	1995-05-26	2004-02-15	Pfizer	Kombinationspräparat zur behandlung der parkinsonschen krankheit, das selektive nmda- antagonisten enthält
GB9515412D0 (en)	1995-07-27	1995-09-27	Pharmacia Spa	2-(4-substituted)-benzylamino-2-methyl-propanamide derivatives
GB9727523D0 (en)	1997-12-31	1998-02-25	Pharmacia & Upjohn Spa	Alpha-aminoamide derivatives useful as analgesic agents
FI109453B (fi)	1999-06-30	2002-08-15	Orion Yhtymae Oyj	Farmaseuttinen koostumus
US20020019421A1 (en) *	2000-07-05	2002-02-14	Roni Biberman	Compositions and therapy for substance addiction
DE10041479A1 (de) *	2000-08-24	2002-03-14	Sanol Arznei Schwarz Gmbh	Neue pharmazeutische Zusammensetzung zur Verabreichung von N-0923
FR2829027A1 (fr) *	2001-08-29	2003-03-07	Aventis Pharma Sa	Association avec un antagoniste du recepteur cb1, les compositions pharmaceutiques les contenant et leur utilisation pour le traitement de la maladie de parkinson

2004
- 2004-04-07 AR ARP040101189A patent/AR044007A1/es unknown
- 2004-04-08 US US10/559,982 patent/US8283380B2/en active Active
- 2004-04-08 DK DK04726590T patent/DK1613296T3/da active
- 2004-04-08 AU AU2004228782A patent/AU2004228782B2/en not_active Expired
- 2004-04-08 CN CN201110271872.8A patent/CN102274517B/zh not_active Expired - Lifetime
- 2004-04-08 EP EP09154864.4A patent/EP2070526B1/de not_active Expired - Lifetime
- 2004-04-08 JP JP2006506582A patent/JP2006522800A/ja active Pending
- 2004-04-08 PT PT04726590T patent/PT1613296E/pt unknown
- 2004-04-08 ES ES09154864.4T patent/ES2454272T3/es not_active Expired - Lifetime
- 2004-04-08 BR BRPI0409364-0A patent/BRPI0409364A/pt not_active Application Discontinuation
- 2004-04-08 KR KR1020117013555A patent/KR20110070929A/ko not_active Ceased
- 2004-04-08 EP EP04726590A patent/EP1613296B1/de not_active Expired - Lifetime
- 2004-04-08 DE DE602004021790T patent/DE602004021790D1/de not_active Expired - Lifetime
- 2004-04-08 SI SI200431192T patent/SI1613296T1/sl unknown
- 2004-04-08 RU RU2005131422/15A patent/RU2342929C2/ru active
- 2004-04-08 PT PT91548644T patent/PT2070526E/pt unknown
- 2004-04-08 PL PL04726590T patent/PL1613296T3/pl unknown
- 2004-04-08 WO PCT/IB2004/001408 patent/WO2004089353A2/en not_active Ceased
- 2004-04-08 NZ NZ542910A patent/NZ542910A/en not_active IP Right Cessation
- 2004-04-08 DK DK09154864.4T patent/DK2070526T3/da active
- 2004-04-08 SI SI200432150T patent/SI2070526T1/sl unknown
- 2004-04-08 AT AT04726590T patent/ATE435012T1/de active
- 2004-04-08 ES ES04726590T patent/ES2326373T3/es not_active Expired - Lifetime
- 2004-04-08 PL PL09154864T patent/PL2070526T3/pl unknown
- 2004-04-08 CA CA2523188A patent/CA2523188C/en not_active Expired - Lifetime
- 2004-04-08 TW TW093109755A patent/TWI340640B/zh not_active IP Right Cessation
- 2004-04-08 MX MXPA05010873A patent/MXPA05010873A/es active IP Right Grant
- 2004-04-08 CN CNA200480009655XA patent/CN1771030A/zh active Pending
- 2004-04-08 KR KR1020057019264A patent/KR101129015B1/ko not_active Expired - Lifetime
2005
- 2005-10-10 NO NO20054640A patent/NO334316B1/no active Protection Beyond IP Right Term
- 2005-10-10 IL IL171331A patent/IL171331A/en active Protection Beyond IP Right Term
2009
- 2009-08-12 CY CY20091100857T patent/CY1109295T1/el unknown
2011
- 2011-11-17 IL IL216403A patent/IL216403A/en active IP Right Grant
2012
- 2012-08-24 US US13/594,621 patent/US8901176B2/en not_active Expired - Lifetime
- 2012-12-14 JP JP2012273371A patent/JP2013067647A/ja active Pending
2013
- 2013-10-28 NO NO20131417A patent/NO335537B1/no unknown
2014
- 2014-04-15 CY CY20141100288T patent/CY1115286T1/el unknown
- 2014-11-04 US US14/532,925 patent/US9492410B2/en not_active Expired - Fee Related
2015
- 2015-07-01 CY CY2015025C patent/CY2015025I1/el unknown
- 2015-07-17 NL NL300752C patent/NL300752I2/nl unknown
- 2015-07-22 LU LU92782C patent/LU92782I2/xx unknown
- 2015-07-22 FR FR15C0054C patent/FR15C0054I2/fr active Active
- 2015-07-22 HU HUS1500043C patent/HUS1500043I1/hu unknown
- 2015-07-23 NO NO2015018C patent/NO2015018I1/no not_active IP Right Cessation

Also Published As

Publication number	Publication date
AU2004228782B2 (en)	2010-05-20
NL300752I2 (de)	2016-07-05
PT1613296E (pt)	2009-07-30
NO335537B1 (no)	2014-12-22
CA2523188A1 (en)	2004-10-21
NO2015018I2 (no)	2015-07-23
ES2454272T3 (es)	2014-04-10
NO334316B1 (no)	2014-02-03
FR15C0054I1 (fr)	2015-11-09
ATE435012T1 (de)	2009-07-15
ES2326373T3 (es)	2009-10-08
KR101129015B1 (ko)	2012-04-20
PL1613296T3 (pl)	2009-12-31
SI2070526T1 (sl)	2014-05-30
HUS1500043I1 (hu)	2018-11-28
NZ542910A (en)	2007-10-26
CY1115286T1 (el)	2017-01-04
DE602004021790D1 (de)	2009-08-13
IL216403A (en)	2015-01-29
EP2070526B1 (de)	2014-02-26
TWI340640B (en)	2011-04-21
US20130053368A1 (en)	2013-02-28
FR15C0054I2 (fr)	2018-01-26
NO20054640L (no)	2005-12-09
US20070093495A1 (en)	2007-04-26
NO2015018I1 (no)	2015-08-03
JP2013067647A (ja)	2013-04-18
AR044007A1 (es)	2005-08-24
EP1613296A2 (de)	2006-01-11
CY2015025I2 (el)	2016-04-13
RU2342929C2 (ru)	2009-01-10
CA2523188C (en)	2012-09-25
SI1613296T1 (sl)	2009-10-31
TW200505423A (en)	2005-02-16
RU2005131422A (ru)	2006-04-27
DK2070526T3 (da)	2014-03-24
EP1613296B1 (de)	2009-07-01
NO20131417L (no)	2005-12-09
WO2004089353A8 (en)	2005-09-01
KR20110070929A (ko)	2011-06-24
CN102274517A (zh)	2011-12-14
KR20060010745A (ko)	2006-02-02
CY2015025I1 (el)	2016-04-13
JP2006522800A (ja)	2006-10-05
NO20054640D0 (no)	2005-10-10
BRPI0409364A (pt)	2006-04-25
DK1613296T3 (da)	2009-10-05
WO2004089353A3 (en)	2004-12-16
US8283380B2 (en)	2012-10-09
IL171331A (en)	2012-03-29
PT2070526E (pt)	2014-03-31
EP2070526A1 (de)	2009-06-17
PL2070526T3 (pl)	2014-08-29
MXPA05010873A (es)	2006-03-21
WO2004089353A2 (en)	2004-10-21
US8901176B2 (en)	2014-12-02
US20150150833A1 (en)	2015-06-04
CY1109295T1 (el)	2014-07-02
IL216403A0 (en)	2011-12-29
US9492410B2 (en)	2016-11-15
AU2004228782A1 (en)	2004-10-21
CN102274517B (zh)	2018-08-31
CN1771030A (zh)	2006-05-10

Publication	Publication Date	Title
LU92782I2 (fr)	2015-09-22	Safinamide à utiliser en combinaison avec levodopa/PDI, et éventuellement avec d'autres médicaments PD, pour le traitement de la maladie de Parkinson
EP1727567A4 (de)	2010-10-13	Zur behandlung von erkrankungen in verbindung mit dem komplementsystem geeignete aptamer-therapeutika
WO2005034998A3 (en)	2005-08-11	Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions
GB0404693D0 (en)	2004-04-07	Pharmaceutical preparations for the treatment of ocular surface and other disorders
EP1850880A4 (de)	2010-09-22	Aptamer-therapeutika zur behandlung komplementär hervorgerufener erkrankungen
IL190150A0 (en)	2008-08-07	New pyrimidine derivatives and their use in therapy as well as the use of pyrimidine derivatives in the manufacture of a medicament for prevention and/or treatment of alzheimer's disease
EP1676512A3 (de)	2008-12-10	Artikel zum behandeln der Haut und Verfahren
PL1656372T3 (pl)	2013-08-30	Związki 2,4-pirymidynodiaminy do stosowania w leczeniu lub zapobieganiu chorobom autoimmunologicznym
EP2035412A4 (de)	2011-02-16	Muskarinrezeptoragonisten, die bei der behandlung von schmerzen, alzheimer-krankheit und schizophrenie effektiv sind
IL195431A0 (en)	2009-08-03	Muscarinic receptor agonists that are effective in the treatment of pain, alzheimer's disease and schizophrenia
IL177787A0 (en)	2006-12-31	1-aminovyclohexane derivatives for the treatment of agitation and other behavioral disorders, especially those associated with alzheimer's disease
FR2886851B1 (fr)	2007-10-05	Composition a base d'une avermectine et de metronidazole notamment pour le traitement de la rosacee
EP1737428A4 (de)	2010-12-22	Makromolekulare abgabesysteme für die nichtinvasive darstellung, untersuchung und behandlung von arthritis und anderen entzündlichen erkrankungen
FR2866340B1 (fr)	2006-11-24	Derives d'oxazole, leur preparation et leur utilisation en therapeutique.
DZ3141A1 (fr)	2001-01-14	Inhibiteurs d'aminotransferase acides aminés-dépendante à chaîne ramifiée, et leur utilisation dans le cadre du traitement de la rétinopathie diabétique.
IL185300A0 (en)	2008-02-09	New pharmaceutical compositions useful in the treatment of parkinson's disease
BRPI0811538A2 (pt)	2015-08-11	Uso de ciclosporinas no tratamento de pacientes com lentes intraoculares.
PL378360A1 (pl)	2006-03-20	Sposób leczenia choroby Parkinsona u ludzi za pomocą infuzji do skorupy czynnika neurotroficznego pochodzącego z gleju
EP1855679A4 (de)	2014-07-23	Aminomethyl-beta-sekretase-hemmer zur behandlung von alzheimer
IL195441A0 (en)	2009-08-03	Use of trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthaleneamine and its formamide in the preparation of medicaments for the treatment of pain disorders
ITRM20050446A1 (it)	2007-02-20	Uso di stilbeni idrossilati e glucosidati per la prevenzione ed il trattamento di patologie oculari.
FR2918282B1 (fr)	2009-10-02	Medicament pour le traitement de la maladie de parkinson
EP2272497A3 (de)	2011-03-23	Verfahren zur Erhöhung der Lymphfunktion
FR2886850B1 (fr)	2007-10-05	Composition a base d'une avermectine et de peroxyde de benzoyle notamment pour le traitement de la rosacee
EP2137156A4 (de)	2011-06-22	Oral biologisch verfügbare prodrugs von (+)-3-hydroxymorphinan zur prävention bzw. behandlung von parkinson-krankheit